首页> 外文期刊>Drug development and industrial pharmacy >Preparation and testing of cyclosporine microsphere and solution formulations in the treatment of polyarthritis in rats.
【24h】

Preparation and testing of cyclosporine microsphere and solution formulations in the treatment of polyarthritis in rats.

机译:制备和测试环孢素微球和溶液制剂治疗大鼠多关节炎。

获取原文
获取原文并翻译 | 示例
           

摘要

We prepared a microencapsulated sustained-release formulation of cyclosporine A (CsA) and compared its efficacy to the solution formulation of cyclosporine A (Sandimmune, Sandoz) in an attempt to improve the treatment of rheumatoid arthritis. Microspheres containing cyclosporine were prepared with poly(lactic co-glycolic acid) (PLGA), a polymer in the submicron particle range of 0.22-0.8 micron. Studies were carried out to determine uptake rates and mechanisms of lymphocyte inhibition mediated by macrophages containing CsA microspheres in vitro. The results of these studies were used to establish whether lower doses of the microencapsulated cyclosporine could be used in in vivo studies in the polyarthritic rat model for rheumatoid arthritis. In vitro dissolution testing revealed that CsA was released extremely slowly from microspheres for up to 48 hr (0.002%). Radiolabeled 3H CsA was incorporated into some PLGA microspheres or the microspheres were labeled using a 99mTc radioligand when needed, and radiolabeling efficiency was consistently above 50%. Uptake studies at various microsphere-to-macrophage ratios (1:1, 1:5, 1:10) were carried out using 99mTc radiolabeled microspheres and macrophages obtained from normal and polyarthritic rats. Normal macrophages behaved significantly differently from arthritic macrophages throughout the study. Arthritic macrophages cause increased amounts of CsA to be released (68% of the dose) into the culture medium past 24 hr compared to normal macrophages (48% of the dose). This factor may account for the significantly increased inhibition (68.2%) of mixed lymphocyte culture proliferation in the presence of arthritic macrophages containing CsA-loaded PLGA microspheres over normal macrophages (48.2%) that were pre-exposed to the same microsphere dose. The equivalent quantity of CsA as that contained in the microspheres when placed in solution or the same quantity of blank PLGA microspheres caused decreased levels of lymphocyte inhibition when compared to the effects of CsA microspheres in macrophages of normal cells, but significantly decreased levels of inhibition in arthritic cells. From the in vivo studies, it is evident that CsA microspheres, even at low dose levels, were highly effective in inhibiting polyarthritis in rats.
机译:我们制备了环孢霉素A(CsA)的微囊缓释制剂,并将其功效与环孢霉素A(Sandimmune,Sandoz)的溶液制剂进行了比较,以试图改善类风湿关节炎的治疗。用聚乳酸-乙醇酸共聚物(PLGA)制备含有环孢菌素的微球,所述聚乳酸是亚微米颗粒范围为0.22-0.8微米的聚合物。进行了研究以确定体外由含CsA微球的巨噬细胞介导的淋巴细胞吸收速率和抑制机制。这些研究的结果用于确定在多关节炎类风湿关节炎模型的体内研究中是否可以使用较低剂量的微囊化环孢素。体外溶出度测试表明,CsA从微球释放的过程非常缓慢,长达48小时(0.002%)。将放射性标记的3H CsA掺入某些PLGA微球中,或在需要时使用99mTc放射性配体标记微球,并且放射性标记效率始终高于50%。使用从正常和多关节炎大鼠获得的99mTc放射性标记的微球和巨噬细胞,以各种微球与巨噬细胞比率(1:1、1:5、1:10)进行摄取研究。在整个研究中,正常巨噬细胞的行为与关节炎巨噬细胞明显不同。与正常的巨噬细胞(剂量的48%)相比,关节炎巨噬细胞在24小时后释放到培养基中的CsA量增加(占剂量的68%)。该因素可能解释了在含有CsA负载的PLGA微球的关节炎巨噬细胞的存在下,混合淋巴细胞培养物增殖的抑制作用显着增加(68.2%),而正常巨噬细胞(48.2%)已预先暴露于相同的微球剂量。与CsA微球对正常细胞巨噬细胞的作用相比,当将CsA微球中所含的当量CsA置于溶液中或相同数量的空白PLGA微球中时,引起的淋巴细胞抑制水平降低,但CsA微球对正常细胞巨噬细胞的抑制作用却明显降低。关节炎细胞。根据体内研究,很明显,即使在低剂量水平下,CsA微球也能有效抑制大鼠多关节炎。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号